The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...
not rated yet |
0
(Medical Xpress)—For many patients with non-small-cell lung carcinoma (NSCLC), tumorigenesis is fueled by mutations that hyperactivate the epidermal growth factor receptor (EGFR) signaling protein. These ...
5 / 5 (1) |
0
Adding lung cancer drugs to targeted melanoma treatment could increase survival for certain patients, according to research published in Cancer Discovery today.
not rated yet |
0
|
New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
not rated yet |
0
A team of neuroscientists and chemists from the U.S. and China today publish research suggesting that a class of currently used anti-cancer drugs as well as several previously untested synthetic compounds show effectiveness ...
4.8 / 5 (4) |
0
|
New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.
not rated yet |
0
|
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies ...
not rated yet |
0
